ReviewNature reviews. Rheumatology2013
Targeting inflammasomes in rheumatic diseases.
Review in Nature reviews. Rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Cardio-Rheumatic Diseases: Inflammasomes Behaving Badly.International journal of molecular sciences · 2025Review
- The Role of Interleukin-17A and NLRP3 Inflammasome in the Pathogenesis of Graves' Ophthalmopathy.Life (Basel, Switzerland) · 2023Article
- Centrality of Myeloid-Lineage Phagocytes in Particle-Triggered Inflammation and Autoimmunity.Frontiers in toxicology · 2021Review
- Disease-Modifying Anti-rheumatic Drug Prescription Baihu-Guizhi Decoction Attenuates Rheumatoid Arthritis via Suppressing Toll-Like Receptor 4-mediated NLRP3 Inflammasome Activation.Frontiers in pharmacology · 2021Article
- Familial Mediterranean fever phenotype progression into anti-cyclic citrullinated peptide antibody-positive rheumatoid arthritis:a case report.Fukushima journal of medical science · 2020Article
- Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils.Arthritis research & therapy · 2019Article
- Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease.Arthritis research & therapy · 2019Article
- Exploring the Involvement of NLRP3 and IL-1Mediators of inflammation · 2019Article
- NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis.Clinical and experimental immunology · 2018Article
- IL-1β Enhances Wnt Signal by Inhibiting DKK1.Inflammation · 2018Article
- COPs and POPs Patrol Inflammasome Activation.Journal of molecular biology · 2018Review
- What rheumatologists need to know about CRISPR/Cas9.Nature reviews. Rheumatology · 2017Review
- A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.Frontiers in pharmacology · 2016Article
- The inflammasome in fibromyalgia and CRPS: a microglial hypothesis?Nature reviews. Rheumatology · 2015Article
- Article
- Small-molecule control of cytokine function: new opportunities for treating immune disorders.Current opinion in chemical biology · 2014Review
- The role of inflammasome in Alzheimer's disease.Ageing research reviews · 2014Review
- CASPASE-12 and rheumatoid arthritis in African-Americans.Immunogenetics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammasomes are key inducers of inflammation in response to exogenous and endogenous stimuli, because they regulate the processing and secretion of the proinflammatory cytokines IL-1β and IL-18. Thus, inflammasomes have a crucial role in host defence against infection, but they can also be involved in inflammatory diseases. Indeed, the NLRP3 (NOD-, LRR- and pyrin domain-containing 3) inflammasome has been shown to play a part in several inflammatory rheumatic disorders, although the mechanisms involved are better elucidated in some of these diseases than in others. In particular, the pathogenesis of cryopyrin-associated periodic syndromes and microcrystal-induced arthritides is thought to be dependent on activation of the NLRP3 inflammasome, and IL-1 inhibition has shown efficacy as a therapeutic strategy in both groups of conditions. In this Review, we describe the current understanding of the mechanisms that trigger the inflammasome, and consider the relevance of the inflammasome to a variety of rheumatic diseases. In addition, we discuss the current therapies targeting this molecular complex, as well as future therapeutic prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.